Suppr超能文献

一项计算结构生物学研究,旨在了解人类内向整流钾离子通道 Kir6.2 突变对其结构-功能关系的影响。

A computational structural biology study to understand the impact of mutation on structure-function relationship of inward-rectifier potassium ion channel Kir6.2 in human.

机构信息

Department of Biotechnology & Bioinformatics, Yogi Vemana University, Kadapa, Andhra Pradesh, India.

出版信息

J Biomol Struct Dyn. 2021 Mar;39(4):1447-1460. doi: 10.1080/07391102.2020.1733666. Epub 2020 Mar 4.

Abstract

Type 2 diabetes (T2D) is clinically characterized via hyperglycemia. Polymorphism rs5219 in the gene is a risk factor for developing T2D in humans. encodes the 'inward-rectifier potassium ion channel (Kir6.2)'. However, because of the absence of the complete crystal/NMR structures of Kir6.2 proteins, insight into its structure and function and its interaction with diverse ligands remain elusive to date. Therefore, a computational approach was employed for predicting the best plausible 'three-dimensional' structure of Kir6.2 as well as for studying the influence of mutation (p. GLU23LYS) on both architectures as well as the function of Kir6.2 employing simulation studies. Results obtained revealed that though, with increased time, 'Gibbs free energy' becomes positive, residues in wild type Kir6.2 experiences less random movement as compared to mutant Kir6.2. The less random movement of residues in wild type Kir6.2 represents the standard coupling between open and closing of 'K channel' and thus the normal secretion of insulin. The more dispersed motion of mutant Kir6.2 residues represents 'overactivity' of the 'K channel' and thus insulin 'under-secretion'. Further, molecular docking and simulation studies identified two phytochemicals/drugs, namely, A-348441 and chushizisin I, which retains the wild type property of Kir6.2 after binding with mutant protein. Unlike A-348441, this is for the first time, the present study is reporting about the plausible anti-diabetic property of chushizisin I. As these two phytochemicals/drugs, namely, A-348441 and chushizisin I, have passed ADMET test, in the near future, they may be utilized as anti-diabetic drugs after further investigation.Communicated by Ramaswamy H. Sarma.

摘要

2 型糖尿病(T2D)的临床特征为高血糖。基因中的 rs5219 多态性是人类发生 T2D 的危险因素。该基因编码“内向整流钾离子通道(Kir6.2)”。然而,由于 Kir6.2 蛋白的完整晶体/NMR 结构尚未完全确定,因此迄今为止,人们对其结构和功能及其与各种配体的相互作用仍知之甚少。因此,采用计算方法来预测 Kir6.2 的最佳“三维”结构,并通过模拟研究来研究突变(p. GLU23LYS)对两种结构以及 Kir6.2 功能的影响。研究结果表明,尽管随着时间的推移,“吉布斯自由能”变为正值,但与突变型 Kir6.2 相比,野生型 Kir6.2 中的残基随机运动较少。野生型 Kir6.2 中残基的这种较少的随机运动代表了“K 通道”的开放和关闭之间的标准偶联,从而实现了胰岛素的正常分泌。突变型 Kir6.2 残基的更分散的运动代表“K 通道”的“过度活动”,从而导致胰岛素“分泌不足”。此外,分子对接和模拟研究鉴定了两种植物化学物质/药物,即 A-348441 和 chushizisin I,它们在与突变蛋白结合后保留了 Kir6.2 的野生型特性。与 A-348441 不同,这是首次报道 chushizisin I 具有合理的抗糖尿病特性。由于这两种植物化学物质/药物 A-348441 和 chushizisin I 均通过 ADMET 测试,因此在不久的将来,在进一步研究后,它们可能被用作抗糖尿病药物。由 Ramaswamy H. Sarma 交流。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验